Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasDiseaseAcute Promyelocytic LeukemiaSubgroupICD10C92.4-MeSHLeukemia, Promyelocytic, AcuteSequenceAPL2016, arm A1: APL2006 V4.1 - A1, A2 and A3, Ind., APL, up to 70, leukoc. up to 10000/µl (PID1035) -|- 1st cons. (PID1042) -|- 2nd cons. (PID1043) -|- maint. (PID1053)APL2016, arm A2: APL2006 V4.1 - A1, A2 and A3, Ind., APL, up to 70, leukoc. up to 10000/µl (PID1035) -|- 1st cons. (PID1044) -|- 2nd cons. (PID1045) -|- maint. (PID1053)APL2016, arm A3: APL2006 V4.1 - A1, A2 and A3, Ind., APL, up to 70, leukoc. up to 10000/µl (PID1035) -|- 1st cons. (PID1046) -|- 2nd cons. (PID1047) -|- maint. (PID1053)APL2016, Arm B: APL2006 V4.1 - B - Ind., APL, older 70, leukoc. up to 10000/µl (PID1054) -|- 1st cons. (PID1055) -|- 2nd cons. (PID1056) -|- maint., C1 (PID1057) -|- maint., C2-5 (PID1058) -|- maint., C6-8 (PID1062)APL2016, arm C1: APL2006 V4.1 - C1 and C2, Ind., APL, up to 70, leukoc. above 10000/µl (PID1048) -|- 1st cons. (PID1049) -|- 2nd cons. (PID1050) -|- maint. (PID1053)APL2016, arm C2: APL2006 V4.1 - C1 and C2, Ind., APL, up to 70, leukoc. over 10000/µl (PID1048) -|- 1st cons. (PID1051) -|- 2nd cons. (PID1052) -|- maint. (PID1053)APL2016, Arm D: APL2006 V4.1 - D - Ind., APL, over 70, leukoc. over 10000/µl (PID1059) -|- 1st cons. (PID1060) -|- 2nd cons. (PID1061) -|- maint., C1 (PID1057) -|- maint., C2-5 (PID1058) -|- maint., C6-8 (PID1062)LPA2005: TRET22.5/IDAR12, APL ind., high-risk (PID1118) -|- 1st cons. (PID1115) -|- 2nd cons. (PID1116) -|- 3rd cons. (PID1117) -|- maint. (PID1119)TRET45/ARSE0.15, Ind., APL (PID652) -|- Cons., C1-3 (PID653) -|- Cons., C4 (PID656)ChemotherapyChemo-substanceArsenic TrioxideCytarabineDexamethasoneIdarubicinMercaptopurineMethotrexateMethylprednisoloneMitoxantroneTretinoinChemo-substanceArsenic TrioxideCytarabineDexamethasoneIdarubicinMercaptopurineMethotrexateMethylprednisoloneMitoxantroneTretinoinChemo-substanceArsenic TrioxideCytarabineDexamethasoneIdarubicinMercaptopurineMethotrexateMethylprednisoloneMitoxantroneTretinoinChemo-substanceArsenic TrioxideCytarabineDexamethasoneIdarubicinMercaptopurineMethotrexateMethylprednisoloneMitoxantroneTretinoinNo. Substances23456 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneGranisetronPosaconazolePrednisoloneSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneGranisetronPosaconazolePrednisoloneSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneGranisetronPosaconazolePrednisoloneSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneGranisetronPosaconazolePrednisoloneNo. Substances12345Protocol classificationTherapy classificationcurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineTherapy phaseConsolidationInductionMaintenanceTherapy intentioncurativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlDifferentiation syndromeDyspneaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityInfectionsNeutropeniaPainQTc Time ExtensionRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorAvvisati GFenaux PLo-Coco FSanz ADiseaseAktue Promyelozyten Leukämie, Hochrisiko (Leukozyten >10 000/µl), ECOG 1-3APL mit t(15;17) und/oder PML-RARA Rearrangement, Erstlinieniedriges bis mittleres Risiko der akuten Promyelozyten Leukämie, ECOG 0-2OriginEuropean APL GroupGIMEMA, AIEOP, and EORTC Cooperative Groups, AIDA 0493GIMEMA, AMLSG und SAL, APL0406Hospital Universitario La Fe, Valencia, SpainProtocols in Revision 30 protocols foundProtocols under revision.APL2006 V4.1 - A1 - Idarubicin 12 / Cytarabine 200, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1042 V1.0)APL2006 V4.1 - A1 - Idarubicin 9 / Cytarabine 1000, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1043 V1.0)APL2006 V4.1 - A1, A2 and A3, Tretinoin 45 / Idarubicin 12 / Cytarabine 200, induction, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1035 V1.0)APL2006 V4.1 - A1, A2, A3, C1, and C2 - Mercaptopurine 90 / Methotrexate 15 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, up to 70 years of age (PID1053 V1.0)APL2006 V4.1 - A2 - Idarubicin 12 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1044 V1.0)APL2006 V4.1 - A2 - Idarubicin 9 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1045 V1.0)APL2006 V4.1 - A3 - Tretinoin 45 / Idarubicin 12, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1046 V1.0)APL2006 V4.1 - A3 - Tretinoin 45 / Idarubicin 12, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1047 V1.0)APL2006 V4.1 - B - Idarubicin 9 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, older than 70 years, leukocytes up to 10000/µl (PID1055 V2.0)APL2006 V4.1 - B - Tretinoin 45 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, older than 70 years of age, leukocytes up to 10000/µl (PID1056 V1.0)APL2006 V4.1 - B - Tretinoin 45 / Idarubicin 9, induction, Acute Promyelocytic Leukemia, older than 70 years, leukocytes up to 10000/µl (PID1054 V1.0)APL2006 V4.1 - B and D, Arsenic Trioxide 0.15, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 2-5 (PID1058 V1.0)APL2006 V4.1 - B and D, Mercaptopurine 90 / Methotrexate 150 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 1 (PID1057 V1.0)APL2006 V4.1 - B and D, Mercaptopurine 90 / Methotrexate 150 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 6-8 (PID1062 V1.0)APL2006 V4.1 - C1 - Idarubicin 12 / Cytarabine 200, 1st consolidation, Acute Promyelocytic Leukemia, up to 70, leukoc. over 10000/µl (PID1049 V1.0)APL2006 V4.1 - C1 - Idarubicin 9 / Cytarabine 1000, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1050 V1.0)APL2006 V4.1 - C1 and C2, Tretinoin 45 / Idarubicin 12 / Cytarabine 200, induction, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1048 V1.0)APL2006 V4.1 - C2 - Idarubicin 12 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1051 V1.0)APL2006 V4.1 - C2 - Idarubicin 9 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1052 V1.0)APL2006 V4.1 - D - Idarubicin 9 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1060 V1.0)APL2006 V4.1 - D - Tretinoin 45 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1061 V1.0)APL2006 V4.1 - D - Tretinoin 45 / Idarubicin 9 / Cytarabine 120, induction, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1059 V1.0)Tretinoin 22.5 / Idarubicin 12, Acute Promyelocytic Leukemia, induction, high risk (PID1118 V2.0)Tretinoin 45 / Arsenic Trioxide 0.15, Induction, Acute Promyelocytic Leukemia (PID652 V1.1)Tretinoin 45 / Arsenic Trioxide 0.15, consolidation, Acute Promyelocytic Leukemia, cycle 1-3 (PID653 V1.1)Tretinoin 45 / Arsenic Trioxide 0.15, consolidation, Acute Promyelocytic Leukemia, cycle 4 (PID656 V1.1)Tretinoin 45 / Idarubicin 12 / Cytarabine 150, Acute Promyelocytic Leukemia, 3rd consolidation, high risk (PID1117 V1.0)Tretinoin 45 / Idarubicin 5 / Cytarabine 1000, Acute Promyelocytic Leukemia, 1st consolidation, high risk (PID1115 V1.0)Tretinoin 45 / Mercaptopurine 50 / Methotrexate 15 , Acute Promyelocytic Leukemia, maintenance, high risk (PID1119 V1.0)Tretinoin 45 / Mitoxantrone 10, Acute Promyelocytic Leukemia, 2nd consolidation, high risk (PID1116 V1.0)
